Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in ...

Zynex Inc. ZYXI recently announced the completion of the clinical verification trial of its NiCO pulse oximeter, which was ...

Zynex has completed the clinical verification trial of its pulse oximeter, NiCO, marking a significant milestone towards the ...

HC Wainwright reissued their buy rating on shares of Zynex (NASDAQ:ZYXI – Free Report) in a report issued on Friday morning,Benzinga reports. The brokerage currently has a $17.00 target price on the ...

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke ...

Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in ...

Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, ...

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynex (ZYXI – Research Report) and KalVista ...

Check the time stamp on this data. Updated AI-Generated Signals for Zynex Inc. (ZYXI) available here: ZYXI.

Zynex Inc (NASDAQ:ZYXI) announced that it has completed the clinical verification trial for its NiCO pulse oximeter, a key milestone required to get market clearance for the device from the US ...

Zynex (ZYXI) has completed its clinical verification trial for their NiCO pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University. Trial completion is a key milestone ...